Exacerbation de BPCO - Partie 2

La très attendue deuxième partie du podcast sur l'exacerbation de BPCO est en ligne! C'est de traitement qu'il est question ici principalement : bronchodilatateurs, corticoïdes, antibiotiques, oxygène, VNI, ... Ouvrons grand nos oreilles!
Références :
Abdo WF, Heunks LM. Oxygen-induced hypercapnia in COPD: myths and facts. Crit Care. 2012 Oct 29;16(5):323 (pubmed.ncbi.nlm.nih.gov/23106947)
Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010 Oct 18;341:c5462. (bmj.com/content/341/bmj.c5462)
Hoult G, Gillespie D, Wilkinson TMA, Thomas M, Francis NA. Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis. BMC Pulm Med. 2022 May 13;22(1):194. (pubmed.ncbi.nlm.nih.gov/35549921)
DundeeChest. Why do COPD patients retain CO2 when given too much oxygen? (dundeechest.wordpress.com/2009/08/12/why-do-co…)
Ligue pulmonaire suisse. Guide de poche BPCO. (liguepulmonaire.ch/sites/default/files/documen…)
Miravitlles M, Moragas A, Hernández S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013 Nov;144(5):1571-1577. (pubmed.ncbi.nlm.nih.gov/23807094)
Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest. 2005 Jul;128(1):48-54 (pubmed.ncbi.nlm.nih.gov/16002915)
Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–1613. (atsjournals.org/doi/10.1164/ajrccm.161.5.9908022)
Ramakrishnan S, Jeffers H, Langford-Wile B, et al. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial. Lancet Respir Med 2024; 12: 67–77. (thelancet.com/journals/lanres/article/PIIS2213…)00298-9/fulltext)
Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020 May;166:105938. (pubmed.ncbi.nlm.nih.gov/32250871)